Safety and toxicological evaluation of a novel, water-soluble undenatured type II collagen

Toxicology Mechanisms and Methods

Volumn 23, Issue 7, 2013, Pages 491-499

  Yoshinari, Orie ^a   Marone, Palma Ann ^b   Moriyama, Hiroyoshi ^a   Bagchi, Manashi ^a   Shiojima, Yoshiaki ^a  

^a Ryusendo Co Ltd   (Japan)

^b Eurofins Medinet Inc   (Germany)

Author keywords

Acute dermal toxicity; Acute oral toxicity; Ames' bacterial reverse mutation assay; Long term safety; Mouse lymphoma assay; Primary dermal irritation; Primary eye irritation; Water soluble type II collagen

Indexed keywords

CLASTOGEN; COLLAGEN TYPE 2; EPITOPE; THYMIDINE KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL MUTATION; BLOOD CHEMISTRY; BODY WEIGHT; BREATHING RATE; CARTILAGE; CHICKEN; CONTROLLED STUDY; DOSE RESPONSE; EXPERIMENTAL DOG; EYE IRRITATION; EYE TOXICITY; FEMALE; HEART RATE; IN VITRO STUDY; IN VIVO STUDY; LD 50; LYMPHOMA; MALE; METABOLIC ACTIVATION; MOUSE; MUTAGENICITY; NONHUMAN; PRIORITY JOURNAL; RAT; REVERTANT; SAFETY; SALMONELLA TYPHIMURIUM; SCORING SYSTEM; SKIN IRRITATION; SKIN TOXICITY; TOXICITY TESTING;

ANIMALS; COLLAGEN TYPE II; FEMALE; LETHAL DOSE 50; MALE; MUTAGENICITY TESTS; RABBITS; RATS; SOLUBILITY; WATER;

EID: 84883391621     PISSN: 15376516     EISSN: 15376524     Source Type: Journal    
DOI: 10.3109/15376516.2013.781255     Document Type: Article

References (31)

1. Ames BN, McCann J, Yamasaki E. (1977). Methods for the Salmonella mutagenicity test. In: Kilbey BJ, ed. Handbook of mutagenicity test procedures. Amsterdam: Elsevier, 1-17.
2. Arthritis Foundation. Osteoarthritis: what is it? Available from: http://www.arthritis.org/disease-center.php?disease-id32 [last accessed 16 April 2010].
3. Bagchi D, Moriyama H, Raychaudhuri SP, eds. (2011). Arthritis: pathophysiology, prevention and therapeutics. Boca Raton (FL): CRC Press/Taylor & Francis.
4. Barnett ML, Combitchi D, Trentham DE. (1996). A pilot trial of oral type II collagen in the treatment of juvenile rheumatoid arthritis. Arthritis Rheum 39:623-8.
5. Barnett ML, Kremer JM, St Clair EW, et al. (1998). Treatment of rheumatoid arthritis with oral type II collagen. Results of a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 41:290-7.
6. Berenbaum F. (2008). New horizons and perspectives in the treatment of osteoarthritis. Arthritis Res Ther 10:S1.
7. Bitton R. (2009). The economic burden of osteoarthritis. Am J Manag Care 15:S230-5.
8. Clive D. (1983). Viable chromosomal mutations affecting the TK locus in L5178Y/TK\+/mouse lymphoma cells: the other half of the assay. Ann NY Acad Sci 407:253-7.
9. Clive D, McCuen R, Spector JF, et al. (1983). Specific gene mutations in L5178Y cells in culture. Mutat Res 115:225-51.
10. Clive D, Spector JF. (1975). Laboratory procedure for assessing specific locus mutations at the TK locus in cultured L5178Y mouse lymphoma cells. Mutat Res 31:17-29.
11. Draize JH, Woodward G, Calvery HO. (1944). Methods for the study of irritation and toxicity of substances applied topically to the skin and mucous membrane. J Pharm Exp Ther 82:377-90.
12. FDA. (1987). Good laboratory practices (GLP) for non-clinical laboratory studies. In Department of Health and Human Services. Washington, DC: US Food and Drug Administration, 297-310.
13. Felson DT, Lawrence RC, Dieppe PA, et al. (2000). Osteoarthritis: new insights. Part 1: the disease and its risk factors. Ann Intern Med 133: 635-46.
14. Gingerich DA, Strobel JD. (2003). Use of client-specific outcome measures to assess treatment effects in geriatric, arthritic dogs: controlled clinical evaluation of a nutraceutical. Vet Ther 4:56-66.
15. Goggs R, Vaughan-Thomas A, Clegg PD, et al. (2005). Nutraceutical therapies for degenerative joint diseases: a critical review. Crit Rev Food Sci Nutr 45:145-64.
16. Helmick CG, Felson DT, Lawrence RC, et al. (2008). Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum 58:15-25.
17. Hootman JM, Helmick CG. (2006). Projections of the US prevalence of arthritis and associated activity limitations. Arthritis Rheum 54: 226-9.
18. Kay JH, Calandra JC. (1962). Interpretation of eye irritation tests. J Soc Cos Chem 13:281-9.
19. Lawrence RC, Felson DT, Helmick CG, et al. (2008). Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum 58:26-35.
20. Maron DM, Ames BN. (1983). Revised methods for the Salmonella mutagenicity test. Mutat Res 113:173-215.
21. McCarthy G, O'Donovan J, Jones B, et al. (2007). Randomised doubleblind, positive-controlled trial to assess the efficacy of glucosamine/chondroitin sulfate for the treatment of dogs with osteoarthritis. Vet J 174:54-61.
22. Mitchell AD, Auletta AE, Clive D, et al. (1997). The L5178Y/TK\+/mouse lymphoma specific gene and chromosomal mutation assay a phase III report of the U.S. Environmental Protection Agency Gene-Tox Program. Mutat Res 394:177-303.
23. National Research Council. (2011). Guide for the care and use of laboratory animals. 8th ed. Washington, DC: National Research Council.
24. OECD. (1998). OECD environmental health and safety publications. Paris: Committee, C. G. a. M. Principles of Good Laboratory Practice Organization for Economic Cooperation and Development.
25. Sarzi-Puttini P, Cimmino MA, Scarpa R, et al. (2005). Osteoarthritis: an overview of the disease and its treatment strategies. Semin Arthritis Rheum 35:1-10.
26. Sauvé F, Paradis M, Refsal KR, et al. (2003). Effects of oral administration of meloxicam, carprofen, and a nutraceutical on thyroid function in dogs with osteoarthritis. Can Vet J 44:474-9.
27. The Mayo Clinic. Osteoarthritis: causes. Available from http://www. mayoclinic.com/health/osteoarthritis/DS00019/DSECTIONcauses [last accessed 9 Feb 2009].
28. Trentham DE. (1996). Evidence that type II collagen feeding can induce a durable therapeutic response in some patients with rheumatoid arthritis. Ann NY Acad Sci 778:306-14.
29. Trentham DE, Dynesius-Trentham RA, Orav EJ, et al. (1993). Effects of oral administration of type II collagen on rheumatoid arthritis. Science 261:1727-30.
30. Trentham DE, Halpner AD, Trentham RA, et al. (2001). Use of undenatured type II collagen in the treatment of rheumatoid arthritis. Clin Pract Altern Med 2:254-9.
31. Yoshinari O, Shiojima Y, Moriyama H. et al. (2013). Effects of watersoluble undenatured type II collagen on collagen-induced arthritic mice. J Med Food (communicated).